Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New DNA-based test for assessing risk of prostate cancer is launched by deCODE

DeCODE Genetics : 11 February, 2008  (New Product)
deCODE genetics has launched deCODE PrCa, a reference laboratory test for common, single-letter variations in the human genome (SNPs) that the company has associated with increased risk of prostate cancer.
deCODE believes the test will be useful for predicting risk of prostate cancer, helping to optimise both screening and treatment. deCODE PrCa detects a total of six previously discovered SNPs that have been confirmed in many populations, as well as two SNPs on chromosomes X and 2 that are reported by deCODE scientists in a paper published in the online edition of Nature Genetics.

Although most of the variants individually confer moderate risk, they are common and some are linked to more than less aggressive disease. Consequently, a substantial proportion of men have many risk variants that together confer clinically significant risk. Because of these variants, 10 percent of men are at twice the risk and one percent of men are at three times the risk of the disease in the general population.

'Through deCODE PrCa, we are bringing together in one tool all of the major genetic risk factors for prostate cancer that we have discovered over the past eighteen months. We believe that this is a test with significant clinical utility for improving and personalising the screening and treatment of one of the most common cancers. At the same time, we will integrate today's discovery into the prostate cancer module in our personal genome analysis service deCODEme, enabling our subscribers to stay abreast of how the latest discoveries in human genetics may relate to their genome,' said Kari Stefansson, CEO of deCODE.

The discovery is a result of the genome-wide analysis of over 300,000 SNPs in 23,000 Icelanders in deCODE's prostate cancer studies, a finding subsequently replicated in a total of more than 15,500 individuals from seven different cohorts from Europe and the USA. One of the SNPs is located on the X chromosome and the other SNP is located on chromosome 2p15 and is associated with a more aggressive form of prostate cancer.

deCODE PrCa is the latest in a series of reference laboratory DNA-based tests for assessing risk of and improving prevention and treatment for common diseases.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo